Simultaneous improvement of physical stability, dissolution, bioavailability, and antithrombus efficacy of Aspirin and Ligustrazine through cocrystallization

Int J Pharm. 2022 Mar 25:616:121541. doi: 10.1016/j.ijpharm.2022.121541. Epub 2022 Feb 3.

Abstract

A novel 1:1 cocrystal between two cardiovascular drugs, aspirin (ASA) and ligustrazine (tetramethylpyrazine, TMP) has been synthesized and characterized. The structure of this drug-drug cocrystal, ASA-TMP, was determined using single crystal X-ray crystallography. The ASA-TMP cocrystal exhibits a significantly reduced sublimation tendency than TMP. Importantly, cocrystallization simultaneously improves bioavailability of both parent drugs. This suggests the possibility of developing a more effective antithrombosis drug therapy given the synergistic pharmacological effects of the two parent drugs.

Keywords: Antithrombosis; Aspirin; Bioavailability; Cocrystal; Ligustrazine.

MeSH terms

  • Aspirin*
  • Biological Availability
  • Crystallization
  • Pyrazines
  • Solubility

Substances

  • Pyrazines
  • Aspirin
  • tetramethylpyrazine